Pfizer’s COVID vaccine data raise some flags, analysts say, but not enough to scuttle an FDA nod

When the FDA released a 53-page briefing document on Pfizer’s COVID-19 mRNA vaccine candidate yesterday, most readers zeroed in on the shot’s high efficacy in a wide range of demographic groups. Wall Street analysts dug a bit deeper.

Their conclusion? A few red flags in the FDA documents will likely generate some discussion at Thursday's advisory panel meeting, but not enough alarm to scuttle an emergency authorization.